CD4 and lung carcinoma: Moreover, for patients with low CD4+ count, no significant differences in survival outcome were seen between CD4+ count <200/mL (11.46 ± 2.72 months) and CD4+ count >200/mL (15.70 ± 2.34 months) (p = 0.324), which demonstrated that HIV+ patients with lung cancer did not seem to be particularly immunosuppressed.